Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KROSNASDAQ:QURENASDAQ:SBTXNASDAQ:TOCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKROSKeros Therapeutics$13.49-0.4%$14.07$9.12▼$72.37$547.96M1.31861,809 shs657,126 shsQUREuniQure$14.21-5.9%$14.20$3.73▼$19.18$778.42M0.081.94 million shs3.31 million shsSBTXSilverback Therapeutics$15.80-0.7%$14.33$2.80▼$8.97$569.72M0.6337,931 shs1.34 million shsTOCATocagen$14.66+17.8%$32.24$0.42▼$6.77$350.65M0.011.47 million shs140,805 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKROSKeros Therapeutics0.00%-0.52%-7.41%+17.92%-70.95%QUREuniQure0.00%-7.37%-6.27%-3.79%+209.59%SBTXSilverback Therapeutics0.00%+2.66%+8.82%+27.83%+93.39%TOCATocagen0.00%+21.31%+94.95%+79.44%+2,899.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKROSKeros Therapeutics3.4841 of 5 stars4.33.00.00.00.05.00.6QUREuniQure1.9446 of 5 stars3.51.00.00.01.32.50.6SBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKROSKeros Therapeutics 2.50Moderate Buy$30.56126.51% UpsideQUREuniQure 2.91Moderate Buy$37.82166.14% UpsideSBTXSilverback Therapeutics 0.00N/AN/AN/ATOCATocagen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TOCA, KROS, QURE, and SBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025KROSKeros TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$32.00 ➝ $18.005/30/2025KROSKeros TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$15.005/30/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.005/29/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.005/19/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025KROSKeros TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$41.00 ➝ $26.005/12/2025QUREuniQureGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/12/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $25.005/6/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/21/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKROSKeros Therapeutics$3.55M154.36N/AN/A$14.11 per share0.96QUREuniQure$27.12M28.70N/AN/A($0.14) per share-101.50SBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ATOCATocagen$40K8,766.31N/AN/A$0.45 per share32.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKROSKeros Therapeutics-$187.35M-$0.18N/AN/AN/A1.96%0.75%0.69%8/6/2025 (Estimated)QUREuniQure-$239.56M-$4.39N/AN/AN/A-1,077.05%-483.87%-34.28%8/7/2025 (Estimated)SBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ATOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/ALatest TOCA, KROS, QURE, and SBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025QUREuniQure-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million5/6/2025Q1 2025KROSKeros Therapeutics-$0.01$3.62+$3.63$3.62$84.62 million$211.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKROSKeros TherapeuticsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKROSKeros TherapeuticsN/A19.2919.29QUREuniQure1.5311.9911.99SBTXSilverback TherapeuticsN/A67.8767.87TOCATocagen1.881.151.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKROSKeros Therapeutics71.56%QUREuniQure78.83%SBTXSilverback Therapeutics74.89%TOCATocagen21.42%Insider OwnershipCompanyInsider OwnershipKROSKeros Therapeutics22.90%QUREuniQure4.79%SBTXSilverback Therapeutics34.40%TOCATocagen10.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKROSKeros Therapeutics10040.62 million31.31 millionOptionableQUREuniQure50054.78 million52.15 millionOptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableTOCATocagen7723.92 millionN/ANot OptionableTOCA, KROS, QURE, and SBTX HeadlinesRecent News About These CompaniesTocagen plummets on phase 3 data for glioma therapyFebruary 2, 2025 | pharmaphorum.comCelgene hopes device + drug can tackle aggressive brain tumoursSeptember 18, 2024 | pharmaphorum.comForte Biosciences Inc (FBRX)August 7, 2024 | investing.comAnova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM GrantMay 1, 2024 | finance.yahoo.comGlioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.bizMarch 25, 2024 | pharmiweb.comONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline GliomaFebruary 12, 2024 | ascopubs.orgMiami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumorsJanuary 20, 2024 | eurekalert.orgForte Biosciences: Changes In Registrant S Certifying AccountantDecember 12, 2023 | cbonds.comRiskOn International And 3 Other Stocks Under $2 Insiders Are BuyingDecember 11, 2023 | markets.businessinsider.comPrecision and personalized medicine: the leading companies in personalized cancer vaccines revealedNovember 6, 2023 | pharmaceutical-technology.comProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board AppointmentNovember 2, 2023 | finance.yahoo.comFDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma PatientsJuly 26, 2023 | precisionmedicineonline.comGene Therapy Market Report 2023 Provides SWOT Analysis ... - openPRMay 12, 2023 | news.google.comForm DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.comApril 29, 2023 | news.google.comGenomic and transcriptomic analysis of checkpoint blockade ... - Nature.comApril 6, 2023 | news.google.comBelzutifan plus cabozantinib for patients with advanced clear cell ... - The LancetMarch 31, 2023 | news.google.comCurrent drug development and trial designs in neuro-oncology ... - The LancetMarch 28, 2023 | news.google.comCompanion Diagnostics Market is set to experience a significant ... - Digital JournalMarch 27, 2023 | news.google.comOligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital JournalMarch 14, 2023 | news.google.comAnaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital JournalMarch 8, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTOCA, KROS, QURE, and SBTX Company DescriptionsKeros Therapeutics NASDAQ:KROS$13.49 -0.06 (-0.44%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$13.48 -0.01 (-0.04%) As of 06/20/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.uniQure NASDAQ:QURE$14.21 -0.89 (-5.89%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$14.02 -0.20 (-1.37%) As of 06/20/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Silverback Therapeutics NASDAQ:SBTX$15.80 -0.11 (-0.69%) As of 06/20/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Tocagen NASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
